NewLink Genetics Corp. has “deprioritized” pancreatic cancer and will not proceed with a planned Phase II study testing its lead product indoximod with AstraZeneca PLC's Imfinzi (durvalumab), the company said during its first-quarter earnings announcement.
This follows on from news last month that NewLink had halted the Phase III Indigo301 study of indoximod in combination...






